CONCLUSION Estrogen with an osteoblast P4R-acting progestin ( EPT ) in these five published RCT provides Level 1 evidence that MPA caused significantly greater annual percent spinal BMD gains than the same dose of ET .
OBJECTIVE To assess whether progesterone ( P4 ) or osteoblast P4 receptor-acting progestin ( P ) contributed to estrogen ( E ) therapy-related  increased areal bone mineral density ( BMD ) in r and omized controlled trials ( RCT ) with direct r and omization to estrogen ( ET ) or estrogen-progestin ( EPT ) therapy .
Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate.
The purpose of this study was to contrast the effects of conventional estrogen treatment with medroxyprogesterone on cancellous and cortical bone change in the first year following premenopausal ovariectomy .  This 1-year double-blind r and omized therapy trial was stratified by osteoporosis family history and performed in an academic medical center and community hospitals . Premenopausal women 45 + /- 5 years old , postovariectomy for benign diseases were provided 600 mg/day of calcium and r and omized to daily therapy with conjugated equine estrogen ( CEE , 0.6 mg ) or medroxyprogesterone ( MPA , 10 mg ) . The primary outcome variable was spinal quantitative computed tomography ( QCT ) bone density change over 1 year with additional outcomes of dual-energy X-ray absorptiometry ( DXA ) of proximal femur ( FN ) , whole body ( WB ) , and spine segment ( WBS ) and N-telopeptide , bone-specific alkaline phosphatase , and other bone marker , hormonal , and weight changes . Results in the 33 women completing the study , whose initial bone densities were normal ( QCT 133 mg/cm3 , femoral neck 0.94 g/cm2 , whole body DXA 1.13 g/cm2 ) , showed annual QCT loss during CEE therapy of -11.5 mg/cm3 ( p < 0.0007 ) and MPA bone loss of -19.7 mg/cm3 ( p < 0.0001 ) . Losses were marginally greater on MPA than CEE ( p = 0.04 ) . Extremely high postovariectomy ( 5 days ) and pretreatment resorption markers ( > 3 SD above premenopausal normal levels ) were significantly related to bone loss . Across the year , resorption decreased during CEE but increased on MPA treatment . Significant DXA bone losses were prevented by CEE treatment ( -1.4 % FN , -.4 % WB , and -1.5 % WBS , all NS ) . However , DXA bone loss was not prevented by MPA treatment ( -5 % FN , -2.8 % WB , and -6.1 % WBS , all p < 0.03 ) . Average weight gain was significant ( + 3.2 + /- 4.0 kg ) and greater on CEE than MPA ( + 4.7 vs. + 2.0 kg , p = 0.049 ) . In conclusion , CEE therapy did not prevent significant 8 % cancellous spinal bone loss in the first year following premenopausal ovariectomy , despite supplementation with 600 mg/day of calcium , good control of vasomotor symptoms , and nearly 5 kg of gain in weight . Significant DXA bone loss , however , was prevented by CEE , but not by MPA therapy . These unexpected results were statistically related to high bone resorption following ovariectomy , which CEE suppressed but MPA did not . Bone formation markers increased during MPA therapy but were unchanged during CEE therapy
CONCLUSION Estrogen with an osteoblast P4R-acting progestin ( EPT ) in these five published RCT provides Level 1 evidence that MPA caused significantly greater annual percent spinal BMD gains than the same dose of ET .
OBJECTIVE To assess whether progesterone ( P4 ) or osteoblast P4 receptor-acting progestin ( P ) contributed to estrogen ( E ) therapy-related  increased areal bone mineral density ( BMD ) in r and omized controlled trials ( RCT ) with direct r and omization to estrogen ( ET ) or estrogen-progestin ( EPT ) therapy .